Kinematic Modeling in Parkinson s Disease

Similar documents
Visualization and simulated animations of pathology and symptoms of Parkinson s disease

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

A. General features of the basal ganglia, one of our 3 major motor control centers:

Basal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota

A. General features of the basal ganglia, one of our 3 major motor control centers:

Basal ganglia Sujata Sofat, class of 2009

Basal Ganglia General Info

Simplified Model of Machado-Joseph Disease in Comparison to Parkinson s Disease and Normal Models

Levodopa vs. deep brain stimulation: computational models of treatments for Parkinson's disease

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

Dr. Farah Nabil Abbas. MBChB, MSc, PhD

Making Things Happen 2: Motor Disorders

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

GBME graduate course. Chapter 43. The Basal Ganglia

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Damage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Basal Ganglia George R. Leichnetz, Ph.D.

MOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement

Lecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!

Teach-SHEET Basal Ganglia

Strick Lecture 4 March 29, 2006 Page 1

Detection of Parkinson S Disease by Speech Analysis

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

PMT. Mark Scheme (Results) January GCE Biology (6BI05) Paper 01 Energy, Exercise and Coordination

III./3.1. Movement disorders with akinetic rigid symptoms

COGNITIVE SCIENCE 107A. Motor Systems: Basal Ganglia. Jaime A. Pineda, Ph.D.

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Visualization and Quantification of the Striato pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Parkinson's Disease KP Update

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

INFLUENCE OF STRENGTH ON MOTOR CONTROL AND GAIT VARIABILITY IN PERSONS WITH PARKINSONS DISEASE

A Gray-Box Neural Network Model of Parkinson s Disease Using Gait Signal

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

UNDERSTANDING PARKINSON S DISEASE

Basal Ganglia. Introduction. Basal Ganglia at a Glance. Role of the BG

Deep Brain Stimulation Surgery for Parkinson s Disease

Movement Disorders: A Brief Overview

Using Sources in the GDP

Biological Bases of Behavior. 8: Control of Movement

Chapter 8. Control of movement

Exam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system

Functional Distinctions

The motor regulator. 1) Basal ganglia/nucleus

Treatment of Parkinson s Disease: Present and Future

Deep Brain Stimulation: Indications and Ethical Applications

Anatomy of the basal ganglia. Dana Cohen Gonda Brain Research Center, room 410

For more information about how to cite these materials visit

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Non-motor subtypes of Early Parkinson Disease in the Parkinson s Progression Markers Initiative

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Pushing the plasticity: The role of exercise in the management of neurological illness

I: To describe the pyramidal and extrapyramidal tracts. II: To discuss the functions of the descending tracts.

BASAL GANGLIA. Dr JAMILA EL MEDANY

Basal nuclei, cerebellum and movement

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Safinamide: un farmaco innovativo con un duplice meccanismo d azione

Surgical Treatment for Movement Disorders

Clinical Features and Treatment of Parkinson s Disease

Medical Surveillance of Manganese exposed workers

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Precise evaluation of motor and non-motor dysfunction in Parkinson s disease using the KINARM

The Parkinson s You Can t See

Parkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. What is Parkinson s Disease?

Palladotomy and Pallidal Deep Brain Stimulation

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

Parkinson s disease (PD) is a neurodegenerative disorder that mainly affects individuals

EFFECT OF QIGONG EXERCISE ON SLEEP QUALITY AND GAIT PERFORMANCE IN PARKINSON S DISEASE Derek J. Wassom

symptoms of Parkinson s disease EXCEPT.

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING

The Shaking Palsy of 1817

CNS MCQ 2 nd term. Select the best answer:

Parkinson s Disease. Gillian Sare

Pilates as a modality to increase movement and improve quality of life for those suffering from Parkinson s Disease

Evaluation and Management of Parkinson s Disease in the Older Patient

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Connections of basal ganglia

Sensitivity analysis for parameters important. for smallpox transmission

Study of Verbal Working Memory in Patients with Parkinson s Disease

UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Spike Sorting and Behavioral analysis software

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Optimizing Clinical Communication in Parkinson s Disease:

Data Mining Tools used in Deep Brain Stimulation Analysis Results

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Biomedical Technology Research Center 2011 Workshop San Francisco, CA

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

NS219: Basal Ganglia Anatomy

STRUCTURE AND CIRCUITS OF THE BASAL GANGLIA

Transcription:

Kinematic Modeling in Parkinson s Disease Alexander Hui Department of Bioengineering University of California, San Diego La Jolla, CA 92093 alexhui@ucsd.edu Abstract Parkinson s disease is a slowly progressing neurological disorder that affects motor function, resulting in bradykinesia, resting tremor, rigidity, and postural instability. The symptoms are associated with a loss of dopaminergic neurons in the brain, and a loss of dopamine is considered the primary defect in Parkinson s disease. Recently, models of Parkinson s disease have been constructed, including one that focuses on bradykinesia in Parkinson s disease. Here, the full model with 26 equations is analyzed with principal component analysis for the purposes of dimensionality reduction. The results of principal component analysis and results of several simulations are presented, which appear to show rigidity, another characteristic of Parkinson s disease. 1 Introduction 1.1 Parkinson s Disease Background Parkinson s disease (PD) is a neurodegenerative disease characterized by motor dysfunction[1]. Clinical manifestations of PD may include bradykinesia (slowness of movement), resting tremor, rigidity, gait abnormalities, and postural instability. Of these clinical symptoms, bradykinesia, resting tremor, rigidity, and postural instability are considered the four cardinal symptoms. Resting tremor is a tremor that occurs when the limb is at rest, and diminishes upon movement. Rigidity is thought to be associated with an increase in muscle tone. Postural instability poses balance difficulties for patients and may lead to falls and injury. Bradykinesia refers to slowness of movement as well as in its initiation and planning. Bradykinesia can progress to a severely debilitating akinesia, or a complete inability for voluntary movement. The symptoms of PD are thought to arise from a decrease in stimulatory signals from the basal ganglia to the motor cortex. PD is often considered a disease in which there is a loss of dopamine. This line of thought is supported by some current treatment approaches in PD. L-dopa is one of the most widely used treatments for PD, and works by being transformed into dopamine in dopaminergic neurons. Dopamine agonists have also been developed, and are fairly effective in treatment of PD. For more advanced PD, an alternative treatment option includes deep brain stimulation, which was approved by the FDA as a treatment for PD in 2002. Although the exact cause of PD is unknown, and diagnosis is clinical, careful studies show that PD involves alterations in neural circuits in the basal ganglia regulating movement. Degeneration of dopamine neurons is observed in the substantia nigra pars compacta and in the striatum. BENG260 Final Project. 1

1.2 Mathematical Models of Parkinson s Disease In recent years, several mathematical models of PD have been formulated. Mostly recently, neural network model of PD bradykinesia was published by Cutsuridis and Perantonis in 2006[2]. The model focuses on the bradykinesia aspects of PD, which is one of the most characteristic clinical manifestations of PD. The model is a multimodular model including basal ganglia, cortex, and spinomusculo-skeletal modules. The model builds and extends on previous models of PD and incorporates the effects of dopamine at several sites in the network, including parameters for the modulatory effect of dopamine at several areas[3]. The model is able to simulate some of the experimentally observed movement and neuronal measurements in PD patients. Effects of dopamine depletion at several sites can then be tested to lend insight into PD disease processes. 1.3 Model Reduction The Cutsuridis model is a system of 26 differential equations. Multiple techniques exist for dimension reduction, including principal component analysis, Fisher s linear discriminant, multidimensional scaling, and independent component analysis. Principal component analysis is the most commonly used dimension reduction technique, and we use this technique here to reduce the dimensions of the model by projecting to a lower dimensional space. 2 Methods 2.1 Implementation All simulations were performed on a 2.5 GHz Intel Core 2 Duo Mac with MATLAB R2009b. The original Cutsuridis model was downloaded from ModelDB[4] and the model equations were implemented in MATLAB. Differential equations were solved with the built-in MATLAB differential equation solver ODE45. Simulations were performed with normal parameters, and then with basal ganglia output decreased, and with both basal ganglia output and dopamine modulatory effects in the cortex (D1-D4 in the model) reduced. 2.2 Model Reduction by Principal Component Analysis Model reduction was attempted by implementing principal component analysis. Data from the full model simulations were first collected. For each dimension (26 in total), the mean was calculated: µ = 1 N ΣN i=1x i (1) The covariance of the mean-adjusted matrix of data (3025 x 26), with the dimensions along columns and the observations along rows, was calculated in MATLAB with the cov(matrix) command. Eigenvectors and eigenvalues of the covariance matrix were then calculated and ordered by magnitude such that: λ 1 λ 2 λ 3... λ 26 The eigenvalues were then analyzed to determine the feasibility of data reduction. The eigenvalue λ measures the variation in the direction of eigenvector e. Eigenvalues λ that are negligible are discarded in order to reduce dimensionality in the model. The data are then projected onto the selected eigenvectors that are retained. A measure of the proportion of data covered by the first M eigenvalues can be determined as: Σ M i=1 λ i Σ N i=1 λ i (2) 2

3 Results 3.1 Simulations To confirm correct implementation of the model in MATLAB, model simulations were compared to published model figures from Cutsuridis et al., to verify that they could be replicated in MAT- LAB. The plots of the bradykinesia model are shown in Figure 1 and Figure 2. Figure 2 shows a delay in movement initiation, and lower velocity upon movement, for the PD case compared to the normal case, reflecting experimental observations in patients. Figures 1 and 2 are similar or identical to figures in Cutsuridis original paper and verify that the model was implemented correctly in MATLAB. Figure 1: Globus pallidus output signal and alpha-motor neuron activity in normal and PD. To test the effects of dopamine depletion on model dynamics, I then performed two simulations. Basal ganglia output was decreased, and then basal ganglia output was decreased in combination with a decrease in parameters representing dopamine modulatory effect. The most interesting model output from these two simulations are shown in Figure 3. Figure three shows force plots under normal conditions and parameters, under reduced basal ganglia output, and finally, under combined reduced basal ganglia output and reduced dopamine modulatory effects. Of note, force increases for the combined reduced basal ganglia output and reduced dopamine modulatory effects condition. 3.1.1 Model Reduction Principal component analysis was used to attempt dimensionality reduction in the model, as described in the methods section. The eigenvalues calculated are shown in Figure 4. In order to calculate the proportion of data covered by the first M eigenvalues, Eqn. 2 was used and the results plotted as a figure, as shown in Figure 5. The proportion of data covered by the first few eigenvalues is listed in Figure 6. The results show that the principal component covers 72.1% of the data, and retaining two eigenvectors covers 95.7% of the data. 3

Figure 2: Position, velocity, and force in normal and PD. Figure 3: Force in normal, decreased basal ganglia output, and combined decreased basal ganglia output + decreased dopamine modulation conditions. 4

Figure 4: Eigenvalues Figure 5: Proportion of data covered by the first i eigenvalues. 5

Figure 6: Proportion of data covered by retaining the eigenvectors with the largest eigenvalues. 6

4 Discussion The results from the model simulations show an interesting result. When the GO signal is reduced, compared to when the GO signal is reduced in combination with a reduction in dopamine modulatory effects in the cortex, the force of the movement in the model simulation, as seen in Figure 3, shows that force increases to a steady state non-zero value. Although the Cutsuridis model is primarily a model focused on PD bradykinesia, the simulation for the combined reduction in basal ganglia output and dopamine modulation show that the model may also be able to replicate another clinical manifestation of PD, namely, rigidity. Rigidity refers to increased muscle tone, or stiffness, in the muscles. The increased force in the plot for reduced dopamine modulation and basal ganglia output may be interpreted as an increase in rigidity. The principal component analysis of the model shows that 72.1% of the data can be covered by the principal component, while two eigenvectors can represent 95.7% of the data. Directions in which the covariance are small may be neglected. These results show that it maybe possible for this model, with 26 dimensions in the full model, to be reduced to 2 dimensions in a reduced model. A reduced model may provide advantages in phase space analysis and provide further insight into model dynamics. Acknowledgments I would like to thank Dr. Cauwenberghs for his time and help. References [1] MayoClinic. [2] Cutsuridis V, Perantonis S. A neural network model of Parkinson s disease bradykinesia. Neural Netw. 2006;19(4):354-74. [3] Bullock D, Bongers RM, Lankhorst M, Beek PJ. A vector-integration-to-endpoint model for performance of viapoint movements. Neural Netw. 1999;12(1):1-29. [4] Cutsuridis V, Perantonis S. A neural model of Parkinson s disease. ModelDB. Accession: 93422. 7